Pan-cancer investigation of C-to-U editing reveals its important role in cancer development and new targets for cancer treatment

Abstract

RNA editing is prevalent in the transcriptome and is important for multiple cellular processes. C-to-U RNA editing sites (RES) are relatively rare and understudied in humans, compared to A-to-I editing. However, the functional impact of C-to-U editing in human cancers also remains elusive. Here, we conducted the first comprehensive survey of pan-cancer C-to-U RESs. Surprisingly, we found that the same subset of RESs were associated with multiple features, including patient survival, cancer stemness, tumor mutation burden (TMB), and tumor-infiltrated immune cell compositions (ICC), suggesting an RES-mediated close relationship between these features. For example, editing sites for GALM or IFI6 that led to higher expression were linked to lower survival and more cancer stemness. Also, TMB was found to be lower in prostate cancer cases with ICC-associated RESs in CAVIN1 or VWA8 or higher in prostate cancer cases with thymoma. With experimental support, we also found RESs in CST3, TPI1, or TNC that are linked to immune checkpoint blockade by anti-PD1. We also confirmed through experiments that two C-to-U RESs in CSNK2B or RPS14 had different effects on colon cancer cells. Patients with CSNK2B editing, which increased the expression of the oncogene CLDN18, had a lower response to drugs. On the other hand, drugs worked better on people who had RPS14 editing, which greatly increased ribosome production. In summary, our study demonstrated the important roles of C-to-U RESs across cancers and shed light on personalized cancer therapy.

Multi-gradient Permutation Survival Analysis Identifies Mitosis and Immune Signatures Steadily Associated with Cancer Patient Prognosis

“…We also identified the most significant GEARs in individual cancer types, such as TLL1 (BLCA), PGK1 (BRCA), RFXANK (CESC), DPP7 (COAD), VWA8 (KIRC), SCMH1 (LGG), HILPDA (LIHC), TLE1 (LUAD), CD151 (LUSC), ANKRD13A (OV), SOCS2 (PAAD), DRG2 (PRAD), ADAMTS6 (STAD), PSMB8 (THCA), ASS1 (UCEC) (Table 3). Many of these genes were previously reported to associate with tumorigenesis 18,[29][30][31][32][33][34][35][36][37][38][39][40] . For example, TLE1 is known as a transcriptional repressor that promotes cell proliferation, migration, and inhibits apoptosis in LUAD 41,42 .…”